Overview

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Status:
Active, not recruiting

Trial end date:
2021-12-22

Target enrollment:

Participant gender:

Summary

This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Collaborators:

Celgene; Genentech, Inc.
Genentech, Inc.

Treatments:

Azacitidine
Venetoclax